Management and Board
Management
Carolina Trkulja
VD
CEO since 2023.
Born 1984.
Carolina has a PhD in biophysical chemistry from Chalmers University of Technology in Gothenburg. Carolina Trkulja was hired as Chief Innovation Officer at Fluicell, where she led the company's research collaborations. She has broad experience in drug development, with particular expertise in lead generation and preclinical development. Carolina, who is the founder of ObliqueTherapeutics, has contributed to several patents and published her research results in renowned scientific journals. Her previous role as Chief Scientific Officer at Oblique Therapeutics AB has given her extensive experience in research and drug development.
Owns 954,550 shares in Fluicell (February 29, 2024).
Joakim Wahlberg
Chief Financial Officer
CFO since 2023.
Born 1970.
Joakim has a licentiate degree from the School of Economics at the University of Gothenburg and intends to defend his doctoral thesis in business administration at the same university during the winter of 2023/24. Joakim Wahlberg has over two decades of experience leading complex financial operations, including his previous role as CFO at Pulsen Group, where he led the transformative modernization of the finance function. In addition, Joakim is completing his doctorate in business administration at the Gothenburg School of Economics. His research focuses on financial management as a dynamic capability and its role in driving strategic development and fostering innovation within organizations.
Owns 1,222,730 shares in Fluicell (February 29, 2024).
Gavin D. M. Jeffries
CHIEF TECHNOLOGY OFFICER
CTO since 2017.
Born 1980.
Gavin is currently the CTO of Fluicell AB and holds a PhD in Chemistry from the University of Washington, Seattle. He was a research assistant at Chalmers University of Technology for 4 years and has published over forty peer-reviewed scientific publications, with a total number of citations of over a thousand. Gavin is an entrepreneur and founder of two biotechnology and optics companies, inventor of several patents and technologies, and has a strong background in microfluidics, single-cell analysis and optical platform integration.
Owns 1,540,000 shares in Fluicell (February 29, 2024).
Jonas Hannestad
CHIEF MARKETING & COMMUNICATIONS OFFICER
Chief Marketing & Communication Officer since 2020.
Born 1981.
Jonas has a PhD in physical chemistry from Chalmers Institute of Technology, Gothenburg and research experience as a postdoctoral fellow at RISE Research Institutes of Sweden and Chalmers Institute of Technology. Jonas combines his research background with experience from project management in research communication in the borderland between science and art with a focus on the intersection between science, technology and society.
Jonas Hannestad owns 410,652 shares in Fluicell (February 29, 2024).
Board
Stefan Tilk
Chairman of the board since 2016.
Born 1964.
Stefan has a master's degree in technical physics from Chalmers University of Technology and has studied business administration at the Barcelona School of Economics. Stefan has extensive experience in leading and developing companies as CEO of, among others, Nevs AB, Geveko AB and Elof Hanson Group. Stefan has also been former vice president of both Volvo Buses and Volvo Trucks, former vice president of Coor. He has a solid background in business development and is skilled in negotiation, business planning, business management, sales and international business.
Independent in relation to the company and major shareholders.
Owns 527,550 shares in Fluicell through STILK AB (February 29, 2024).
Gavin D. M. Jeffries
Board member since 2012.
Born 1980.
Gavin is currently the CTO of Fluicell AB and holds a PhD in Chemistry from the University of Washington, Seattle. He was a research assistant at Chalmers University of Technology for 4 years and has published over forty peer-reviewed scientific publications, with a total number of citations of over a thousand. Gavin is an entrepreneur and founder of two biotechnology and optics companies, inventor of several patents and technologies, and has a strong background in microfluidics, single-cell analysis and optical platform integration.
Dependent in relation to the company / Independent in relation to major shareholders.
Owns 1,540,000 shares in Fluicell (February 29, 2024).
Owe Orwar
Board member since 2015.
Born 1964.
Owe is Senior Group Leader at Karolinska Institutet. After completing a PhD in chemistry from the University of Gothenburg, he completed two years of postdoctoral studies at Stanford University. Owe has previous experience as Global VP of R&D at Sanofi, President of R&D at Piramal Healthcare, as well as entrepreneur, inventor and founder of six biotechnology companies. Owe has a total of over 20 years of experience in the pharmaceutical and biotechnology industry, holds more than 75 patents, is the author of hundreds of research articles and is a pioneer in the research areas of single-cell biology and biophysics with several products on the global market.
Dependent in relation to the company / Independent in relation to major shareholders.
Owns 611,615 shares in Fluicell through Clavis & Vose Invest AB (February 29, 2024).
Daniel T. Chiu
Board member since 2017.
Born 1972.
Graduated from Harvard, Stanford and UC Berkeley.Daniel has been a professor of chemistry and biotechnology at the University of Washington since 2006. After graduating from Stanford University, he completed postdoctoral research at Harvard University. Scientific founder of several life science and biotech companies in Asia, Europe and the USA. Member and Chair of numerous government and industry advisory and review panels. He is a pioneer in the field of single-cell biology with several products on the global market. Daniel has authored more than 200 scientific publications and is an inventor on over 60 issued patents.
Independence in relation to the company and major shareholders.
Daniel owns no shares in Fluicell
Carl Fhager
Board member since 2017.
Born 1975.
Law degree, Gothenburg University.Carl is an experienced and recognized lawyer at MAQS Gothenburg office. He has extensive experience in commercial agreements, including cooperation, commissions and purchases as well as contractual terms. He specializes in the sports, media and entertainment industry, where he has worked for over ten years, in addition to being the sports director for the football club BK Häcken for four years. Thanks to Carl's dual legal and management background, he has helped many boards in an advisory role, or as a member or chairman.
Independence in relation to the company and major shareholders.
Does not own shares in Fluicell (February 29, 2024).
Regina Fritsche Danielson
Board member since 2022.
Born 1964.
PhD in cardiovascular physiology and pharmacology from Gothenburg University.Regina is Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism at AstraZeneca and leads drug development from target discovery through clinical proof-of-concept in the areas Unmet medical need and Cardiovascular and metabolic diseases. The main focus of the research that Danielson leads is to develop new therapies that can cure disease or stop disease progression, with regenerative approaches and precision medicine as key strategies. Regina is part of the management team for several strategic research collaborations, as well as in the British Heart Foundation Center for Research Excellence (CRE) Cambridge, the Physiological Systems Domain Panel and the Medical Research Council (MRC).
Independent in relation to the company and major shareholders.
Does not own shares in Fluicell (February 29, 2024).